SCHEMBL6355402

SCHEMBL6355402

O=C1Nc2ccccc2/C1=C1\C=Cc2cc(CO)ccc2N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
MAOA P21397 4/20 0.38
MAOB P27338 4/20 0.38
ACVR1 Q04771 2/20 0.37
LRRK2 Q5S007 2/20 0.37
PDGFRA P16234 1/20 0.37
FER P16591 1/20 0.37
LTK P29376 1/20 0.37
CDK8 P49336 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
TGM2 P21980 2/20 0.36
KDR P35968 2/20 0.36
CHEK1 O14757 2/20 0.36
CSNK1G1 Q9HCP0 1/20 0.36
ALDH1A1 P00352 4/20 0.35
MAPT P10636 4/20 0.35
PKM P14618 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355403 1.00 NTRK1 (0.38) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6354754 0.81 KMT2A (0.42) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6354756 0.81 KMT2A (0.42) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6279537 0.80 MAPT (0.50) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6358112 0.80 MAPT (0.50) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6350563 0.80 ACVR1 (0.40) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6350561 0.80 ACVR1 (0.40) NTRK1CCNA2CDK2CCNA1MAOA
SCHEMBL6350535 0.79 PRKCB (0.42) KDRALDH1A1NPSR1KDM4EIDO1
SCHEMBL6353004 0.79 ALDH1A1 (0.38) NTRK1CCNA2CDK2CCNA1ALDH1A1
SCHEMBL6353001 0.79 ALDH1A1 (0.38) NTRK1CCNA2CDK2CCNA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 NTRK1 573/4885CCNA2 632/4885CDK2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.